Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody

hRS7 may represent a novel treatment option for patients with cervical cancer refractory to conventional treatment modalities.